TITLE

THE TREATMENT OF SHOCK ACCOMPANYING MYOCARDIAL INFARCTION

AUTHOR(S)
Bernstein, Arthur; Rothfeld, Edwin L.; Robins, Bernard; Cohen, Frederick; Simon, Franklin
PUB. DATE
November 1963
SOURCE
Angiology;Nov1963, Vol. 14 Issue 11, p559
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
1. Shock in myocardial infarction must be vigorously combatted by increasing cardiac output and coronary blood flow if these patients are to be salvaged. 2. Inotropic, vasoconstrictor vasopressors such as norepinephrine and metaraminol are effective but have the disadvantage of the need for careful tigration, slough at sites of extravascular infiltration and arrhythmia production. 3. Pure vasoconstrictors such as methoxamine are probably best not used in the treatment of cardiogenic shock since they increase cardiac work. 4. Mephentermine sulphate is an inotropic vasopressor which is not a peripheral arterial constrictor, but is a venoconstrictor. It thereby increases cardiac efficiency. It is also antiarrhythmic. 5. Mephentermine was used to treat 80 cases of severe cardiogenic shock. In 61 cases, (76 per cent), there was an initial adequate rise in blood pressure with an ultimate survival rate of 43 per cent of the group. 6. Mephentermine was given in doses of 60 mg intravenously or intramuscularly or both followed by an intravenous drip of 600 to 1200 mg in 500 cc of 5 per cent glucose in distilled water with no evidence of slough, rash, excess rise of blood pressure or undue cerebral stimulation. Precise titration of dose was not needed and tachyphylaxis did not occur using this regime.
ACCESSION #
16434500

 

Related Articles

  • Medication Adherence After Myocardial Infarction: A Long Way Left To Go. Choudhry, Niteesh K.; Winkelmayer, Wolfgang C. // JGIM: Journal of General Internal Medicine;Feb2008, Vol. 23 Issue 2, p216 

    The author reflects on the developments surrounding the medication for the treatment and prevention of myocardial infarction. The medications of coronary heart disease have been subject to various evaluation in trials. Several drugs, which are taken in combination, have been estimated to reduce...

  • Primary angioplasty should be first line treatment for acute myocardial infarction. Smith, David; Channer, Kevin // BMJ: British Medical Journal (International Edition);5/22/2004, Vol. 328 Issue 7450, p1254 

    Presents a medical debate regarding primary angioplasty as a first line treatment for acute myocardial infarction. Relation between normal coronary artery blood flow and mortality after myocardial infarction; Comparison of the methods thrombolysis and coronary angioplasty for restoring blood flow.

  • In-hospital outcomes after primary percutaneous coronary intervention according to left ventricular ejection fraction. Vakili, Hossein; Sadeghi, Roxana; Rezapoor, Parisa; Gachkar, Latif // ARYA Atherosclerosis;2014, Vol. 10 Issue 4, p1 

    BACKGROUND: The primary objective of primary percutaneous coronary intervention (pPCI) in patients with acute ST-segment elevation myocardial infarction (STEMI) is not only to restore the blood flow in the infarct-related artery, but also to save the patients' quality and duration of their life....

  • The heart of the matter. Rosser, Maria // Emergency Nurse;Dec2008, Vol. 16 Issue 8, p22 

    The article explains why primary percutaneous coronary intervention (PPCI) is preferable to thrombolysis as a treatment for patients with acute myocardial infarction (AMI). The key aim of either therapy is the effective restoration of the blood supply to myocardial muscle. In thrombolysis,...

  • Anti-inflammatory mechanisms and therapeutic opportunities in myocardial infarct healing. Kempf, Tibor; Zarbock, Alexander; Vestweber, Dietmar; Wollert, Kai // Journal of Molecular Medicine;Apr2012, Vol. 90 Issue 4, p361 

    The wound healing response after myocardial infarction (MI) involves a cascade of molecular and cellular events that lead to a replacement of the necrotic area with a collagen-rich scar. Clearance of necrotic debris by neutrophils, monocytes, and macrophages is a critical component of infarct...

  • Guidelines-based treatments benefit elderly with MI.  // PharmacoEconomics & Outcomes News;6/13/2009, Issue 580, p6 

    The article discusses research being done on the use of guidelines-recommended treatments in the clinical management of myocardial infarction (MI) in elderly patients. It references a study by F. Schiele and colleagues, published in the April 2009 issue of the "European Heart Journal." The study...

  • Efficacy of Eplerenone for Treatment of Heart Failure. Zepf, Bill // American Family Physician;12/1/2003, Vol. 68 Issue 11, p2256 

    Presents an abstract of the study "Eplerenone, a Selective Aldosterone Blocker, in Patients With Left Ventricular Dysfunction After Myocardial Infarction," by B. Pitt et al., from the April 3, 2003 issue of the "New England Journal of Medicine."

  • Reperfusion Therapy for Acute Myocardial Infarction: Which Strategy for Which Patient? Boersma, E.; Steyerberg, E.W.; van der Vlugt, M.J.; Simoons, M.L. // Drugs;Jul1998, Vol. 56 Issue 1, p31 

    Several modes of reperfusion therapy for evolving myocardial infarction (MI) have been developed, which differ in terms of effectiveness, complexity and costs. Reperfusion resources are often restricted by budgetary or logistical circumstances. To arrive at an equitable distribution of treatment...

  • Stopping aspirin raises CVD mortality risk.  // Pulse;8/10/2011, Vol. 71 Issue 26, p8 

    The article reports that Spanish researchers have found that cessation of aspirin use as secondary prevention for cardiovascular disease can increase the risk of heart attack or coronary heart disease by 50%.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics